C4 Therapeutics to Present Early CFT1946 Monotherapy Data at ESMO 2024

On July 16, 2024, C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company focused on targeted protein degradation science, announced the upcoming presentation of preliminary data from the Phase 1/2 clinical trial of CFT1946. This data will be shared during a mini oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024, scheduled for September 13-17, 2024, in Barcelona, Spain.

The presentation, titled "Preliminary Results from a Phase 1 Study of CFT1946, a Novel BIDAC Degrader in Mutant BRAF V600 Solid Tumors," is set for Saturday, September 14, 2024, from 2:45 to 2:50 CEST. It will take place in the Oviedo Auditorium - Hall 3, under the session category of developmental therapeutics. Dr. Maria Vieito, M.D., Msc, from La Coruña, Spain, will present the findings.

C4 Therapeutics is dedicated to the development of new medicines using targeted protein degradation, aiming to revolutionize patient care. The company is advancing its targeted oncology programs through clinical trials and employs its proprietary TORPEDO® platform to design and optimize small-molecule drugs that target challenging diseases. The goal is to utilize the body's natural protein recycling mechanisms to degrade harmful proteins, which could potentially address drug resistance and improve patient outcomes.

CFT1946 is an orally administered BiDAC™ degrader specifically designed to target BRAF V600X mutant proteins. In preclinical trials, CFT1946 has demonstrated efficacy both in vitro and in vivo, particularly in models where the disease is driven by BRAF V600E mutations and in those resistant to existing BRAF inhibitors. The ongoing Phase 1 dose escalation study is evaluating CFT1946 in patients with BRAF V600X mutant solid tumors, including colorectal cancer, melanoma, and non-small cell lung cancer. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!